Tag: breast cancer diagnostics industry share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Breast Cancer Diagnostics Market Expansion Outlook: What Revenue Opportunities Are Ahead?

The breast cancer diagnostics market has shown strong expansion in recent years. It is anticipated to grow from $5 billion in 2025 to $5.42 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. This historical growth can be linked to several factors, including the increasing global incidence of breast cancer, greater public awareness of early cancer screening, the expansion of diagnostic imaging infrastructure, the rising availability of biomarker-based tests, and enhancements in the accuracy and safety of biopsy procedures.

The breast cancer diagnostics market is anticipated to experience robust expansion over the coming years. Its value is projected to reach $7.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This growth throughout the forecast timeframe stems from factors such as the increasing embrace of precision oncology diagnostics, growing investments in AI-powered diagnostic platforms, a rising need for minimally invasive tests, the expansion of population-wide screening initiatives, and ongoing innovations in molecular diagnostic technologies. Key trends expected during the forecast period involve a greater uptake of AI-assisted imaging analysis, increased utilization of genomic and molecular testing, the expanding implementation of liquid biopsy methods, the broadening application of advanced non-ionizing imaging techniques, and a sharpened emphasis on early and customized diagnosis.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=41656019&type=smp&name=Breast%20Cancer%20Diagnostics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Breast Cancer Diagnostics Market Development Factors: What’s Supporting Demand?

Government initiatives and financial backing for breast cancer are projected to stimulate the expansion of the breast cancer diagnostics market in the future. These government initiatives and funding constitute a form of governmental financial assistance provided to select organizations with proposals or projects that enhance public services and the economy. Such governmental efforts are instrumental in supporting breast cancer research, prevention, and treatment. Various programs are implemented to elevate awareness, advocate for early detection through screening and mammography services, and extend financial aid to underprivileged communities for breast cancer testing and treatment. For example, the Australian Government Department of Health (DoH), a government agency based in Australia, allocated $40.7 million in its 2022-23 budget. This funding was aimed at improving the accessibility of testing and screening services for diverse types of cancers, addressing setbacks from the COVID-19 pandemic, and enabling timely referrals, prompt diagnosis, and early intervention. This sum included $9.7 million specifically allocated for breast cancer screening. Hence, government initiatives and funding focused on breast cancer are fueling the growth of the breast cancer diagnostics market.

Breast Cancer Diagnostics Market Segment Breakdown: Which Categories Lead On Revenue?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Breast Cancer Diagnostics Market Transformation Trends: What Innovations Are Driving Change?

Leading companies in the breast cancer diagnostics market are actively developing innovative AI-driven diagnostic solutions, including advanced pathology scoring platforms, to enhance accuracy, streamline workflows, and enable personalized treatment planning. These AI-based diagnostic platforms employ machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, thereby delivering diagnostic insights or risk stratifications that support clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, introduced its expanded AI platform for breast cancer diagnostics, incorporating a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature into its Ibex Breast HER2 module. This tool effectively identifies invasive cancer areas, classifies HER2 expression levels (0, 1+, 2+, 3+), and aids breast cancer diagnosis and treatment-pathway decisions with improved accuracy and workflow efficiency.

Breast Cancer Diagnostics Market Industry Leaders And Competitive Landscape

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

View The Full Breast Cancer Diagnostics Market Report:

https://thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Breast Cancer Diagnostics Market Regional Analysis And Leading Geography

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Breast Cancer Diagnostics Market Compare Between 2026 And 2030?

The breast cancer diagnostics market size has shown robust growth in recent years. It is projected to increase from $5 billion in 2025 to $5.42 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. The expansion observed in past periods is attributable to factors such as the rising global prevalence of breast cancer, greater public understanding of early cancer screening, the broadening of diagnostic imaging infrastructure, the increasing availability of biomarker-based tests, and advancements in the accuracy and safety of biopsies.

The breast cancer diagnostics market size is projected to experience robust expansion over the upcoming years. This market is set to reach $7.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the forecast period include the expanding use of precision oncology diagnostics, increased investments in AI-powered diagnostic platforms, a heightened demand for less invasive testing methods, the proliferation of population-based screening initiatives, and ongoing innovations in molecular diagnostic technologies. Key trends anticipated for the forecast timeframe involve a greater uptake of AI-assisted imaging analysis, a surge in genomic and molecular testing applications, the broader implementation of liquid biopsy techniques, the spread of advanced non-ionizing imaging modalities, and an intensified emphasis on early and customized diagnosis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

What Primary Factors Are Fueling The Expansion Of The Breast Cancer Diagnostics Market?

Government initiatives and dedicated funding for breast cancer are anticipated to fuel the expansion of the breast cancer diagnostics market moving forward. Such government support encompasses financial aid provided to selected entities whose proposals or projects contribute to and improve public services and the economy. These governmental efforts play a vital role in bolstering breast cancer research, prevention, and treatment, with various programs established to heighten awareness, encourage early detection through screening and mammography services, and provide financial assistance for breast cancer testing and care to underserved communities. As an illustration, The Australian Government Department of Health (DoH), the Australia-based Government agency, earmarked $40.7 million in its 2022-23 budget. This allocation aimed to boost the availability of testing and screening services for diverse cancers, offsetting delays caused by the COVID-19 pandemic, and ensuring timely referrals, rapid diagnosis, and early intervention, with $9.7 million specifically allocated for breast cancer screening. Hence, government initiatives and funding for breast cancer are propelling the growth of the breast cancer diagnostics market.

How Is The Breast Cancer Diagnostics Market Distributed Across Key Segments?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Which Trends Are Guiding The Development Of The Breast Cancer Diagnostics Market?

Leading companies within the breast cancer diagnostics market are prioritizing the creation of innovative AI-powered diagnostic solutions, including advanced pathology scoring platforms, to boost precision, optimize workflows, and enable individualized treatment planning. These AI-driven diagnostic platforms incorporate machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, subsequently providing diagnostic insights or risk stratifications that aid clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, unveiled its expanded AI platform dedicated to breast cancer diagnostics, which notably introduced a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature within its Ibex Breast HER2 module. This tool effectively identifies invasive cancer regions, categorizes HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment-pathway determinations with enhanced accuracy and workflow efficiency.

Who Are The Leading Firms Participating In The Breast Cancer Diagnostics Market?

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Access The Complete Breast Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Region Is The Dominant Market In The Breast Cancer Diagnostics Market?

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Breast Cancer Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Diagnostics Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Breast Imaging Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-imaging-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Breast Cancer Diagnostics Market From 2026 To 2030?

The breast cancer diagnostics market has demonstrated robust growth in recent years. It is projected to expand from $5 billion in 2025 to $5.42 billion in 2026, at a compound annual growth rate (CAGR) of 8.3%. The growth observed in the historic period stems from several factors, including the rising incidence of breast cancer globally, increased awareness of early cancer screening, the expansion of diagnostic imaging infrastructure, the growing availability of biomarker-based tests, and enhancements in biopsy accuracy and safety.

The breast cancer diagnostics market is anticipated to experience substantial growth over the coming years. This market is projected to reach $7.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this anticipated growth include the wider adoption of precision oncology diagnostics, increased investments in AI-powered diagnostic platforms, a rising need for less invasive testing methods, the expansion of widespread screening initiatives, and ongoing innovations in molecular diagnostic technologies. Key trends expected during this period encompass the growing integration of AI-assisted imaging analysis, an uptick in genomic and molecular testing, the increased application of liquid biopsy techniques, the development of sophisticated non-ionizing imaging approaches, and a stronger emphasis on prompt and tailored diagnoses.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

What Significant Factors Are Influencing The Breast Cancer Diagnostics Market Expansion?

Government initiatives and funding directed at breast cancer are anticipated to stimulate the expansion of the breast cancer diagnostics market moving forward. These government initiatives and funding represent a form of financial aid provided by the government to selected entities with concepts or projects that contribute to and enhance public services and the economy. Such governmental support is vital for bolstering breast cancer research, prevention, and treatment, with various programs being rolled out to increase public awareness, encourage early detection through screening and mammography, and provide financial assistance to underserved communities for breast cancer testing and treatment. For example, The Australian Government Department of Health (DoH), the Australia-based Government agency, allocated $40.7 million in its 2022-23 budget to improve access to testing and screening services for different types of cancers, addressing disruptions caused by the COVID-19 pandemic, and facilitating timely referrals, swift diagnosis, and early intervention. This allocation included $9.7 million specifically designated for breast cancer screening. Therefore, government initiatives and funding for breast cancer are instrumental in driving the growth of the breast cancer diagnostics market.

How Are Different Segments Classified In The Breast Cancer Diagnostics Market Segment Analysis?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

What Trends Are Affecting The Direction Of The Breast Cancer Diagnostics Market?

Leading companies in the breast cancer diagnostics market are concentrating on developing innovative AI-powered diagnostic solutions, such as advanced pathology scoring platforms, to boost accuracy, streamline workflows, and enable personalized treatment planning. AI-based diagnostic platforms are defined as technologies that leverage machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, providing diagnostic insights or risk stratifications that support clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, unveiled its expanded AI platform for breast cancer diagnostics, introducing a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature within its Ibex Breast HER2 module. This tool accurately identifies invasive cancer areas, classifies HER2 expression levels (0, 1+, 2+, 3+), and assists breast cancer diagnosis and treatment-pathway decisions with enhanced accuracy and workflow efficiency.

Who Are The Companies Driving Activity In The Breast Cancer Diagnostics Market?

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Get The Full Breast Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Region Dominates The Breast Cancer Diagnostics Market By Market Share?

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Breast Cancer Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Diagnostics Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Breast Imaging Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-imaging-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Breast Cancer Diagnostics Market Across 2026–2030?

The market for breast cancer diagnostics has experienced robust growth recently. This market is projected to expand from $5 billion in 2025 to $5.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.3%. Historically, this expansion has been driven by factors such as a global increase in breast cancer cases, greater public understanding of early cancer detection, the development of diagnostic imaging facilities, the increasing supply of tests based on biomarkers, and advancements in the precision and safety of biopsies.

The breast cancer diagnostics market is projected to undergo significant expansion in the upcoming years. It is forecast to attain a value of $7.28 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. The anticipated growth within this period stems from the increasing integration of precision oncology diagnostics, rising investments directed towards AI-enabled diagnostic platforms, an escalating demand for minimally invasive testing procedures, the widening reach of population-based screening programs, and ongoing progress in molecular diagnostic technologies. Notable trends expected during the forecast period encompass a greater adoption of AI-assisted imaging analysis, an increased utilization of genomic and molecular testing, the growing deployment of liquid biopsy techniques, the expansion of advanced non-ionizing imaging modalities, and an intensified focus on prompt and personalized diagnoses.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

What Drivers Are Shaping The Future Growth Of The Breast Cancer Diagnostics Market?

Public sector programs and financial aid for breast cancer are anticipated to fuel expansion in the breast cancer diagnostics market in the future. These initiatives and funds represent governmental financial backing extended to specific organizations or projects designed to enhance public services and economic conditions. Such government support is crucial for advancing breast cancer research, prevention, and treatment, involving diverse programs aimed at increasing awareness, encouraging early diagnosis via screening and mammography, and offering financial aid for breast cancer testing and treatment in underprivileged areas. As an illustration, The Australian Government Department of Health (DoH), a government body based in Australia, committed $40.7 million in its 2022-23 budget. This allocation aimed to improve access to testing and screening services for multiple cancer types, addressing delays from the COVID-19 pandemic, and facilitating quick referrals, rapid diagnosis, and early interventions, with $9.7 million specifically designated for breast cancer screening. Consequently, governmental programs and financial support directed towards breast cancer are propelling the expansion of the breast cancer diagnostics market.

What Segmentation Levels Are Considered In The Breast Cancer Diagnostics Market?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

What Trends Are Projected To Affect The Breast Cancer Diagnostics Market?

Leading companies in the breast cancer diagnostics market are prioritizing the development of innovative AI-driven diagnostic solutions, such as advanced pathology scoring platforms, to enhance accuracy, streamline workflows, and enable personalized treatment planning. These AI-based diagnostic platforms utilize machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, providing diagnostic insights or risk stratifications that support clinical decision-making. For example, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, introduced its expanded AI platform for breast cancer diagnostics, which includes a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature within its Ibex Breast HER2 module. This specific tool effectively identifies invasive cancer areas, classifies HER2 expression levels (0, 1+, 2+, 3+), and contributes to improved accuracy and workflow efficiency in breast cancer diagnosis and treatment-pathway decisions.

Which Leading Firms Are Contributing To The Growth Of The Breast Cancer Diagnostics Market?

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Read the full breast cancer diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Geographic Regions Are Influencing Demand In The Breast Cancer Diagnostics Market?

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Breast Cancer Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Diagnostics Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Breast Imaging Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-imaging-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the remote patient monitoring market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Breast Cancer Diagnostics Market expected to reach by 2030?

The breast cancer diagnostics market size has demonstrated significant expansion in recent years. This market is forecasted to increase from $5 billion in 2025 to $5.42 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. The drivers behind this historical growth include the escalating global incidence of breast cancer, heightened awareness regarding early cancer screening, the expansion of diagnostic imaging infrastructure, the increasing availability of biomarker-based tests, and enhancements in the accuracy and safety of biopsies.

The breast cancer diagnostics market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $7.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.7%. This anticipated growth can be linked to several factors, including the increasing integration of precision oncology diagnostics, a surge in investments towards AI-powered diagnostic solutions, a heightened need for less invasive testing methods, the broadening scope of population-wide screening initiatives, and ongoing progress in molecular diagnostic technologies. Key developments anticipated during this period encompass the greater adoption of AI-supported imaging analysis, a growing prevalence of genomic and molecular tests, the expanded application of liquid biopsy procedures, an increase in sophisticated non-ionizing imaging options, and a stronger emphasis on early and customized diagnoses.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

What Drivers Are Driving Adoption Within The Breast Cancer Diagnostics Market?

Government initiatives and funding dedicated to breast cancer are projected to accelerate the expansion of the **breast cancer diagnostics market**. These governmental programs and financial assistance constitute a form of public financial backing provided to select entities whose ideas or projects contribute to public services and economic enhancement. Such efforts are vital in supporting breast cancer research, prevention, and treatment, through various programs designed to elevate awareness, encourage early detection via screening and mammography, and deliver financial aid for testing and care to underserved communities. As an illustration, **The Australian Government Department of Health (DoH)**, an Australia-based government agency, earmarked **$40.7 million** in its budget for **2022-23** to bolster access to testing and screening services for diverse cancer types. This allocation aims to mitigate delays caused by the COVID-19 pandemic and ensure timely referrals, prompt diagnoses, and early interventions, with **$9.7 million** of this sum specifically directed towards breast cancer screening. Consequently, these governmental undertakings and financial provisions for breast cancer are actively stimulating the growth of the **breast cancer diagnostics market**.

How Is The Breast Cancer Diagnostics Market Organized Into Various Segments?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Which Trends Are Influencing The Performance And Direction Of The Breast Cancer Diagnostics Market?

Key companies within the breast cancer diagnostics market are prioritizing the creation of innovative AI-powered diagnostic solutions, including advanced pathology scoring platforms, to elevate accuracy, optimize operational flows, and facilitate personalized treatment approaches. AI-based diagnostic platforms encompass technologies that leverage machine learning and deep-learning algorithms to examine medical imaging, pathology slides, or clinical information, providing diagnostic insights or risk categorizations that assist clinical decision-making. For example, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, unveiled its expanded AI platform for breast cancer diagnostics. This launch introduced a fully automated, zero-click HER2 immunohistochemistry (IHC) scoring feature within its Ibex Breast HER2 module. This instrument identifies invasive cancer zones, categorizes HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment-pathway choices with heightened precision and workflow effectiveness.

Who Are The Primary Competitors In The Global Breast Cancer Diagnostics Market?

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Breast Cancer Diagnostics Market?

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Breast Cancer Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Diagnostics Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Breast Imaging Technologies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-imaging-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Uncover key drivers, emerging technologies, and competitive movements shaping the breast cancer diagnostics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Breast Cancer Diagnostics Market Now And By 2029?

The breast cancer diagnostics market size has experienced robust growth in recent years. Projections indicate an expansion from $4.68 billion in 2024 to $5 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by factors such as awareness and screening campaigns, widespread mammography screening, continuous technological advancements, the availability of genetic testing, and a comprehensive multidisciplinary approach.

The market for breast cancer diagnostics is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $6.81 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this growth during the forecast period include the rise of personalized medicine, advancements in liquid biopsies, the adoption of 3D mammography (tomosynthesis), the integration of AI and machine learning, and the increasing use of telemedicine and remote consultations. Key trends characterizing the forecast period encompass breakthroughs in imaging technologies, the evolution of personalized medicine, the development of liquid biopsies, and the application of AI and machine learning.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

Which Long-Term Drivers Are Expected To Sustain The Breast Cancer Diagnostics Market?

The rising occurrence of breast cancer will necessitate more diagnostic equipment, which, in turn, will elevate the demand for the breast cancer diagnostics market. Breast cancer stands as the most common cancer, impacting 2.1 million women annually and accounting for the highest number of cancer-related deaths in women. The objective of early diagnosis is to enhance the percentage of breast cancers identified at an initial stage, allowing for more successful care and a reduction in the risk of death from breast cancer. For instance, in January 2022, the American Cancer Society, a US-based health organization focused on cancer elimination, estimated that roughly 287,850 new cases of invasive breast cancer and 51,400 occurrences of DCIS would be diagnosed in women in the United States in 2022, with an expected 43,250 fatalities attributed to breast cancer. Hence, the increasing incidence of breast cancer is projected to propel the growth of the breast cancer diagnostics market.

How Is The Breast Cancer Diagnostics Market Classified By Different Segments?

The breast cancer diagnosticsmarket covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

How Are Industry Trends Steering The Expansion Of The Breast Cancer Diagnostics Market?

Technological progress represents a significant trend within the breast cancer diagnostics market. A range of new techniques have been developed that hold promise for use in diagnosing and treating breast cancer. For example, 3D mammography, also known as breast tomosynthesis, acquires images around the breast from different angles and transforms them into a 3-D model. In September 2022, Niramai, an Indian Health-Tech company, unveiled an innovative solution named Thermalytix. This is an automated instrument for breast cancer screening and diagnosis that integrates thermal imaging and AI.

Who Are The Primary Market Leaders In The Breast Cancer Diagnostics Market?

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Breast Cancer Diagnostics Market?

North America was the largest region in the breast cancer diagnostics market in 2024. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Diagnostics Market 2025, By The Business Research Company

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Breast Cancer Diagnostics Market Between 2025 And 2029?

The overall scale of the market concerned with diagnosing breast cancer has seen robust expansion lately, projected to increase from its 2024 valuation of $4.68 billion to $5 billion in 2025, reflecting a consistent annual growth trajectory of 7.0 percent, a rise fueled during the past period by factors such as heightened public consciousness and associated screening initiatives, widespread use of mammography for early detection, continuous progress in diagnostic technologies, the increasing relevance of genetic testing, and the adoption of comprehensive, team-based treatment strategies.

Projections indicate the breast cancer diagnostics sector will experience robust expansion moving forward, anticipated to achieve a market valuation of $6.81 billion by the year 2029, driven by a compound annual growth rate (CAGR) approximating eight percent. This upward trajectory throughout the coming forecast window is fundamentally linked to the increasing implementation of personalized medical approaches, the rising utilization of liquid biopsies, the progression of 3D mammography alternatives such as tomosynthesis, the integration of artificial intelligence and machine learning capabilities, as well as greater reliance on telemedicine platforms for remote patient consultations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

Which Drivers Are Supporting Growth Of The Breast Cancer Diagnostics Market?

The rising prevalence of breast cancer necessitates an expanded set of diagnostic tools, consequently fueling greater demand within the breast cancer diagnostics market. Being the most frequently occurring cancer, breast cancer impacts 2.1 million females annually and is responsible for the highest cancer mortality rate among women. The central aim of detecting this disease early is to elevate the proportion of cancers caught in their nascent stages, thereby enabling more efficacious treatment modalities and mitigating the likelihood of mortality stemming from the illness. For illustration, projections released in January 2022 by the American Cancer Society, a US-based entity dedicated to eradicating cancer, estimated that roughly 287,850 new cases of invasive breast cancer alongside 51,400 instances of DCIS would be identified in US women during 2022, with an expected 43,250 deaths linked to breast cancer. Consequently, this escalating rate of breast cancer occurrences is anticipated to be a major impetus for the expansion of the breast cancer diagnostics market.

What Are The Different Segment Classifications Within The Breast Cancer Diagnostics Market?

The breast cancer diagnosticsmarket covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

What Trends Are Expected To Drive The Breast Cancer Diagnostics Market?

Progress in technology serves as a paramount influence shaping the breast cancer diagnostics sector, evidenced by the emergence of multiple novel methodologies applicable for both identifying and managing the disease. Specifically, the imaging procedure termed 3D mammography, or breast tomosynthesis, functions by capturing a series of images around the breast from diverse viewpoints, subsequently compiling these into a three-dimensional representation; furthermore, a notable development occurred in September 2022 when the Indian Health-Tech enterprise Niramai introduced Thermalytix, an advanced screening and diagnostic instrument integrating artificial intelligence with thermal imaging capabilities.

Which Key Market Players Are Investing In Expansion And Innovation Of Breast Cancer Diagnostics Market?

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Geographies Are Emerging As Strong Markets For The Breast Cancer Diagnostics Industry?

North America was the largest region in the breast cancer diagnostics market in 2024. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Breast Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Diagnostics Market 2025, By The Business Research Company

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Breast Cancer Diagnostics Market’s Growth Trajectory From 2025 To 2034?

In the past years, the market size of breast cancer diagnostics has significantly expanded. The market is predicted to escalate from $4.68 billion in 2024 to $5 billion in 2025, with a compound annual growth rate (CAGR) of 7.0%. Factors such as heightened awareness, screening campaigns, mammographic examinations, technological progress, genetic analyses, and a multidisciplinary approach have contributed to this growth.

The market size of breast cancer diagnostics is predicted to witness substantial growth in the coming years. The market is expected to expand to $6.81 billion by 2029, rising at a compound annual growth rate (CAGR) of 8.0%. The predicted growth during the forecast timeframe is associated with factors such as personalized medicine, liquid biopsies, 3D mammography (tomosynthesis), AI and machine learning, telemedicine, and remote consultations. The forecast period also sees key trends such as advancements in imaging technologies, personalized medicine, liquid biopsies, AI and machine learning.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

What are the Fundamental Drivers and Innovations Shaping the Breast Cancer Diagnostics Market?

The growth in cases of breast cancer necessitates advanced diagnostic equipment, thereby stimulating the breast cancer diagnostics market. As the most prevalent type of cancer, breast cancer impacts around 2.1 million women annually, accounting for the highest number of deaths among women due to cancer. Early diagnosis aims to amplify the number of breast cancers identified at the onset, allowing efficacious treatment plans and reducing the mortality rate. To illustrate, the American Cancer Society, a US public health entity dedicated to eradicating cancer, projected in January 2022 that there would be about 287,850 new cases of invasive breast cancer and 51,400 incidences of DCIS diagnosed among women in the US in 2022, with an estimated 43,250 deaths resulting from this disease. Hence the surge in the prevalence of breast cancer is set to propel the expansion of the breast cancer diagnostics market.

How Is the Breast Cancer Diagnostics Market Segmented?

The breast cancer diagnosticsmarket covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Which Regions Are Driving the Next Phase of the Breast Cancer Diagnostics Market Growth?

North America was the largest region in the breast cancer diagnostics market in 2024. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Breast Cancer Diagnostics Market?

A driving force in the breast cancer diagnostics market is the advancement in technology. Various innovative techniques have been introduced that can be utilized in both detecting and curing breast cancer. The creation of 3D mammography or breast tomosynthesis is a prime example – a process which involves capturing images of the breast from multiple angles and converting them into a 3D representation. In September 2022, Niramai, a health-tech enterprise from India, introduced a ground-breaking solution named Thermalytix. This tool, which merges thermal imaging and AI, automates the screening and diagnosis of breast cancer.

View the full report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

How Is the Breast Cancer Diagnostics Market Defined and What Are Its Core Parameters?

Breast cancer diagnostics refer to the various methods, tests, and procedures used to detect and diagnose breast cancer in individuals. These diagnostics help identify the presence of cancer cells in breast tissue, determine the stage of cancer, and guide treatment decisions.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3284

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Breast Cancer Diagnostics Market From 2025 To 2029?

The market size for breast cancer diagnostics has seen a robust expansion in past years. The projected growth is from $4.68 billion in 2024 to $5.04 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%. The growth seen in the historical period can be tied back to factors such as heightened awareness and screening promotions, uses of mammography for screening, advancements in technology, genetic tests, and a multidisciplinary methodology.

What Is the Projected Market Size of the Breast Cancer Diagnostics Market?

Significant expansion is anticipated in the breast cancer diagnostics market in the succeeding years. The projections suggest that the market will reach a value of $6.91 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.2%. The predicted growth can be credited to various factors like personalized medicine, liquid biopsies, 3D mammography (tomosynthesis), artificial intelligence, and machine learning, as well as the advent of telemedicine and remote consultations. The forecast period also promises significant trends such as improvements in imaging technologies, increased focus on personalized medicine, the use of liquid biopsies, and the rise of AI and machine learning.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

Who are the Major Competitors in the Breast Cancer Diagnostics Market Outlook?

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

What Is Fueling Growth in the Breast Cancer Diagnostics Market?

The rise in breast cancer cases necessitates additional diagnostic equipment, thereby boosting the breast cancer diagnostics market’s demand. With breast cancer being the leading type of cancer, it affects around 2.1 million women annually and is the primary cause of cancer-related deaths among women. The primary aim of early diagnosis is to increase the detection rate of breast cancer in its early stages, allowing for more effective treatment and a decreased mortality risk. In January 2022, the American Cancer Society, a health organization from the US focused on cancer eradication, estimated that around 287,850 new cases of invasive breast cancer and 51,400 instances of DCIS would be diagnosed in American women that year, expecting about 43,250 deaths due to breast cancer. As such, the surge in breast cancer cases is predicted to propel the growth of the breast cancer diagnostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Which Breast Cancer Diagnostics Market Segments Are Growing the Fastest?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Which Industry Trends Are Shaping the Future of the Breast Cancer Diagnostics Market?

The progression in technology is a crucial trend within the breast cancer diagnostics market. Numerous innovative methods for diagnosing and treating breast cancer have been created. Breast tomosynthesis, also known as 3D mammography, captures images of the breast from different angles and converts them into a 3D representation. In September 2022, Niramai, a Health-Tech firm from India, unveiled a unique solution named Thermalytix. It is an automatic tool for breast cancer screening and diagnosis that merges thermal imaging with AI.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Countries Are Leading the Breast Cancer Diagnostics Market?

North America was the largest region in the breast cancer diagnostics market in 2023. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3284

This Report Delivers Insight On:

1. How big is the breast cancer diagnostics market, and how is it changing globally?

2. Who are the major companies in the breast cancer diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the breast cancer diagnostics market right now?

4. Which products or customer segments are growing the most in the breast cancer diagnostics market?

5. What factors are helping or slowing down the growth of the breast cancer diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Breast Cancer Diagnostics Market From 2025 To 2029?

The market size for breast cancer diagnostics has seen a robust expansion in past years. The projected growth is from $4.68 billion in 2024 to $5.04 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%. The growth seen in the historical period can be tied back to factors such as heightened awareness and screening promotions, uses of mammography for screening, advancements in technology, genetic tests, and a multidisciplinary methodology.

What Is the Projected Market Size of the Breast Cancer Diagnostics Market?

Significant expansion is anticipated in the breast cancer diagnostics market in the succeeding years. The projections suggest that the market will reach a value of $6.91 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.2%. The predicted growth can be credited to various factors like personalized medicine, liquid biopsies, 3D mammography (tomosynthesis), artificial intelligence, and machine learning, as well as the advent of telemedicine and remote consultations. The forecast period also promises significant trends such as improvements in imaging technologies, increased focus on personalized medicine, the use of liquid biopsies, and the rise of AI and machine learning.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

Who are the Major Competitors in the Breast Cancer Diagnostics Market Outlook?

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

What Is Fueling Growth in the Breast Cancer Diagnostics Market?

The rise in breast cancer cases necessitates additional diagnostic equipment, thereby boosting the breast cancer diagnostics market’s demand. With breast cancer being the leading type of cancer, it affects around 2.1 million women annually and is the primary cause of cancer-related deaths among women. The primary aim of early diagnosis is to increase the detection rate of breast cancer in its early stages, allowing for more effective treatment and a decreased mortality risk. In January 2022, the American Cancer Society, a health organization from the US focused on cancer eradication, estimated that around 287,850 new cases of invasive breast cancer and 51,400 instances of DCIS would be diagnosed in American women that year, expecting about 43,250 deaths due to breast cancer. As such, the surge in breast cancer cases is predicted to propel the growth of the breast cancer diagnostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Which Breast Cancer Diagnostics Market Segments Are Growing the Fastest?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Which Industry Trends Are Shaping the Future of the Breast Cancer Diagnostics Market?

The progression in technology is a crucial trend within the breast cancer diagnostics market. Numerous innovative methods for diagnosing and treating breast cancer have been created. Breast tomosynthesis, also known as 3D mammography, captures images of the breast from different angles and converts them into a 3D representation. In September 2022, Niramai, a Health-Tech firm from India, unveiled a unique solution named Thermalytix. It is an automatic tool for breast cancer screening and diagnosis that merges thermal imaging with AI.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Countries Are Leading the Breast Cancer Diagnostics Market?

North America was the largest region in the breast cancer diagnostics market in 2023. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3284

This Report Delivers Insight On:

1. How big is the breast cancer diagnostics market, and how is it changing globally?

2. Who are the major companies in the breast cancer diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the breast cancer diagnostics market right now?

4. Which products or customer segments are growing the most in the breast cancer diagnostics market?

5. What factors are helping or slowing down the growth of the breast cancer diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model